Osteonecrosis of the mandible releated to bisphosphonate: Report of one case

Abstract

Bisphosphonates are synthetic analogs of pyrophosphates and they are used in the treatment of; hypercalcemia due to malignancies, multiple myeloma, bone metastases and osteoporosis. The use of these medications can minimize the risk of complications due to skeletal anomalies and they are helpful for the pain relief but they can also cause some side effects such as osteonecrosis of the jaws. In this case report, we are discussing the diagnosis and treatment approach for the oral bisphosphonate-induced osteonecrosis of the her left mandibula jaw following the tooth extraction in a 60 years old female patient, together with current literature review

Keywords

• bisphosphonate, jaw, osteonecrosis

Bifosfonat kullanımına bağlı mandibulada gelişen osteonekroz ve tedavi yaklaşımı: olgu sunumu

Abstract

Bifosfonatlar pirofosfatların sentetik analogları olup; malignensilere bağlı olarak gelişen hiperkalsemi, multipl myeloma, kemik metastazı tedavisin yanında osteoporöz tedavisi için kullanılan ilaçlardır. İlacın uygulanması iskeletsel anomalilere bağlı olarak gelişen riskleri minimuma indirerek ağrı kontrolünü sağlasa da, ilacın kullanımına bağlı olarak çene kemiklerinde gelişen osteonekroz gibi yan etkileri de görülebilmektedir. Bu vakada 60 yaşında kadın hastada oral bifosfonat kullanımı ve diş çekimi sonrasında sol mandibula premolar bölgesinde gerçekleşen osteonekrozun teşhisi ve tedavi yaklaşımı anlatılmakta, ayrıca bu tür vakaların diş hekimliği alanındaki önemi güncel literatür bilgisi altında tartışılmaktadır.

Keywords

• bifosfonat tedavisi, çene, osteonekroz

References

1. Delmas PD, Recker RR, Chesnut CH III, Skag R, Stakkestad JA, Emkey R, Gilbride J, Schimmer RC, Christiansen C. Daily and intermittent oral ibandronate normali- ze bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int 2004;15(10):792-8.
2. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in pa- tients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29(8):1548-58.
3. Leite AF, Figueiredo PT, Melo NS, Ace- vedo AC, Cavalcanti MG, Paula LM, Pau- la AP, Guerra EN. Bisphosphonate- associated osteonecrosis of the jaws. Re- port of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(1):14-21.
4. Katz H. Endodontic implications of bip- hosphonate-associated osteonecrosis of the jaws: A report of three cases. J Endod 2005;31(11):831-4.
5. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's disea- se of bone: indication for treatment and re- view of current therapies. J Bone Miner Res 2006;21(2): 94-8.
6. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fas- hola T, Saidi Y, Eriksen EF, Reid IR. Long-term control of bone turnover in Pa- get's disease with zoledronic acid and ri- sedronate. J Bone Miner Res 2007; 22(1):142-8.
7. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate the- rapy: Expert panel recommendations. J Am Dent Assoc 2006;137(8):1144–50.
8. Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The ef- fects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106(1):5-13.

9. Reid IR, Bolland MJ, Grey AB. Is bisp- hosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41(3):318-20.
10. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S,Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66(5):839-47.
11. Junquera L, Gallego L. Nonexposed bisp- hosphonate-related osteonecrosis of the Jaws: another clinical variant? J Oral Maxillofac Surg 2008;66(7):1516-17.
12. Vassiliou V, Tselis N, Kardamakis D. Os- teonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 2010;186(7):367–73.
13. Hino S, Murase R, Terakado N, Shintani S, Hamakawa H. Response of diffuse scle- rosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy. Int J Oral Maxillofac Surg 2005;34(5):576–8.
14. Van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. Br J Oral Maxillofac Surg 2003;41(1):3–6.
15. Marx RE, Sawatari Y, Fortin M, Brou- mand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
16. Yarom N, Lazarovici TS, Elad S. Oral bisphosphonate-related osteonecrosis of the jaw: incidence, clinical features, pre- vention, and treatment recommendations. Clinic 2010;8(1):27–31. Miner Metab
17. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. Task force on bisphosphonate-related os- teonecrosis of the jaws, American Asso- ciation of Oral and Maxillofacial Surge- ons. Aust Endod J 2009;35(3):119-30.
18. Freiberger JJ. The utility of hyperbaric oxygen in treatment of bisphosphonate- related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5):96–106.
19. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Pian- tadosi CA. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw; a case series. J Oral Maxillofac Surg 2007;65(7):1321–7.
20. Lee CY, David T, Nishime M. Use of pla- telet-rich plasma in the management of oral bisphosphonate-associated osteonec- rosis of the jaw: a report of two cases. J Oral Implantol 2007;33(6):371-82.
21. Curi MM, Cossolin GSI, Koga DH, Araşjo SR, Feher O, dos Santos MO, Zardetto C. Treatment of avascular osteonecrosis of the mandible in cancer patients with a his- tory of bisphosphonate therapy by combi- ning bone resection and autologous plate- letrich plasma: report of 3 cases. J Oral Maxillofac Surg 2007;65(2):349–55.
22. Simon BI, Gupta P, Tajbakhsh S. Quanti- tative evaluation of extraction socket hea- ling following the use of autologous plate- le-rich fibrin matrix in humans. Int J Peri- odontics 2011;31(3):285-95. Dent,
23. Chang YC, Zhao JH. Effects of platelet- rich fibrin on human periodontal ligament fibroblasts and application for periodontal infra bony defects. Aust Dent J, 2011;56(4):365-71.
24. Chang IC, Tsai CH, Chang YC. Platelet- rich fibrin modulates the expression of extracellular signal-regulated protein kina- se and osteoprotegerin in human osteob- lasts. 2010;95(1):327-32. Mater Res A,
25. Huang FM, Yang SF, Zhao JH, Chang YC. Platelet-rich fibrin increases prolifera- tion and differentiation of human dental pulp cells. J Endod, 2010;36(10):1628-32.
26. Soydan SS, Uckan S. Management of bip- hosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report. J Oral Maxillofac Surg 2014;72(2):322-6.
27. Senel-Çizmeci F, Baltacıoglu E, Basmacı- Çizmeci F, Bagıs B, Özkaynak Ö, Tosun E. Bifosfonat kullanımına bağlı gelişen mandibula ve maksilla nekrozları ve dental yaklaşım. ADO Klinik Bilimleri Derg 2007;4(1):49-54.
28. Woo SK, Hellstein JW, Kalmar JR. Sys- tematic review: Bisphosphonates and oste- onecrosis of the jaws. Ann Inter Med 2006;144(10):753-61.
29. Melo MD, Obeid G. Osteonecrosis in pati- ents with a history of receiving bisphosp- honate therapy: Strategies for prevention and 2005;136(12):1675-81. JADA
30. Ruggiero S, Gralow J, Marx R, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V. Practical guidelines for the prevention, diagnosis and treatment of os- teonecrosis of the jaw in patients with can- cer. J Oncol Prac 2006;2(1):7-14.